Developer docs
API playgroundTry for free, no card

Search company profiles

20|20 OptimEyes Technologies

Full company profile

uuid000fqti

Namestring
20|20 OptimEyes Technologies
Legal namestring
20|20 OptimEyes Technologies
Company typeenum
Private
Founded yearint
2018
Descriptiontext

20|20 OptimEyes Technologies is a Canadian biotechnology spin-out from McMaster University, founded in 2018 and headquartered in Hamilton, Ontario. The company has developed a proprietary MNP (Mucoadhesive Nanoparticles) drug delivery platform that encapsulates small-molecule active pharmaceutical ingredients in micelle structures with a mucoadhesive binding moiety, enabling sustained, localized release on mucosal surfaces. The core technology is protected by granted patents in the United States (Patent No. 10611908), Europe (EP3344232B1), Canada (CA2996910C), and Japan (JP2018529696A). In vivo data show OptimEyes MNPs achieve 6x greater drug concentration on the ocular surface at one week versus standard mucoadhesive nanoparticles, supporting a reduced dosing frequency advantage.

The company's lead product candidate is a latanoprost-based formulation for glaucoma designed for once-weekly dosing, targeting the up to 50% non-compliance rate observed with current daily topical regimens. A secondary candidate addresses dry eye disease with cyclosporine, demonstrated to achieve equivalent efficacy to Restasis in a rat model when dosed once every three days versus twice daily. The MNP platform is positioned as broadly applicable across ophthalmology, respiratory, urogenital, women's health, oncology, and CNS pathologies. The company pursues a dual go-to-market: internal product development for its own pipeline and external licensing collaborations with pharmaceutical partners for novel therapeutics applications.

20/20 OptimEyes operates as a pre-revenue, pre-commercial biotechnology company with a workforce of 1-10 employees. Revenue generation is anticipated through future product sales upon regulatory approval and through licensing fees, milestone payments, and royalty arrangements with strategic partners. The company has received institutional support from McMaster Seed Fund and Innovation Factory, and in September 2025 won the Blue Ticket Competition co-awarded by SpinUp at U of T Mississauga and Merck, providing wet-lab access, mentorship, and research network connectivity. CEO Frances Lasowski leads the organization. No commercial products, pricing, or revenue have been disclosed.

Short descriptiontext

20/20 OptimEyes Technologies is a pre-revenue McMaster University spin-out developing a patented mucoadhesive nanoparticle (MNP) drug delivery platform, with lead latanoprost glaucoma and cyclosporine dry eye product candidates targeting reduced dosing frequency and improved compliance.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHamilton, Canada
HQ citystring
Hamilton
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
mucosal drug delivery, ophthalmic pharmaceuticals, nanoparticle formulations, drug delivery platform, biotechnology research
Industry2 codes
PRIMARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Nanotechnology541713
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Ophthalmic Pharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Internal Product Development
TypeOne Time License
Description

Developing proprietary drug formulations using existing generic therapeutics (e.g., latanoprost for glaucoma) through the MNP platform to create differentiated products with reduced dosing frequency. Revenue will be generated through product sales upon regulatory approval.

2020optimeyes.ca
2Strategic Partnerships and Licensing
TypeLicensing Royalties
Description

External collaborations with pharmaceutical partners to apply the MNP platform to novel therapeutics. The company offers in vitro and in vivo feasibility and optimization studies for partners. Revenue could come from licensing fees, milestone payments, and royalty arrangements.

2020optimeyes.ca
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

20|20 OptimEyes Technologies develops and commercializes a proprietary Mucoadhesive Nanoparticles (MNP) drug delivery platform that encapsulates small-molecule drugs in mucoadhesive nanoparticles for sustained, localized release to mucosal surfaces. Its lead product candidate is a latanoprost-based once-weekly glaucoma formulation, and its secondary candidate is a cyclosporine-based dry eye disease formulation. The platform is licensed to pharmaceutical partners and applied across ophthalmology, respiratory, urogenital, women's health, oncology and CNS indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 6x greater drug concentration on ocular surface at 1 week compared to standard MNP formulations
+4 more records
Product overview1 text field

20|20 OptimEyes Technologies offers the MNP (Mucoadhesive Nanoparticles) Platform as its core technology, a drug delivery system that encapsulates therapeutics in mucoadhesive nanoparticles for sustained, localized delivery to mucosal surfaces. The company's lead product is a latanoprost-based glaucoma treatment (currently in validation), and its secondary product addresses dry eye disease. Both products leverage the same MNP platform technology, which reduces dosing frequency (potentially to once-weekly) while improving bioavailability and patient compliance compared to conventional topical treatments.

Product and service3 records
1MNP (Mucoadhesive Nanoparticles) Platform
CategoryDrug Delivery Platform / Core Technology
Description

A next-generation mucoadhesive drug delivery platform that encapsulates small-molecule drugs in nanoparticles for sustained, localized release to mucosal surfaces, with improved bioavailability and reduced dosing frequency; licensed to pharmaceutical partners and applicable across ophthalmology, respiratory, urogenital, women's health, oncology and CNS indications.

2Glaucoma Treatment (Latanoprost Formulation)
CategoryLead Product Candidate / Ophthalmic Pharmaceutical
Description

Lead product candidate using the MNP platform with latanoprost as the active pharmaceutical ingredient for the treatment of glaucoma, designed for once-weekly dosing to address the up to 50% non-compliance rate with current daily topical eye drop regimens; targeted at chronic glaucoma patients and prescribing ophthalmologists.

3Dry Eye Disease Treatment (Cyclosporine Formulation)
CategorySecondary Product Candidate / Ophthalmic Pharmaceutical
Description

Secondary product candidate using the MNP platform with cyclosporine for dry eye disease, offering improved tolerability and once-every-three-days dosing versus the twice-daily regimen of currently approved US treatments (Restasis, Cequa, Xiidra); targeted at patients suffering from dry eye disease with limited efficacy or tolerability issues on existing therapies.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-23
Description

SpinUp is the first wet lab startup incubator at the University of Toronto Mississauga campus. 20/20 OptimEyes won the 2025 Blue Ticket Competition, receiving a free one-year membership providing access to subsidized wet lab space, equipment, entrepreneurship programming and resources in a state-of-the-art facility.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-23
Description

Merck (known as MSD outside US and Canada) is providing mentorship and guidance from seasoned Merck scientists and business leaders, along with access to U of T's research talent and network. The partnership supports breakthrough innovation in life sciences and aligns with Merck's commitment to groundbreaking health technologies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

20/20 OptimEyes Technologies is a biotechnology spin-out company from McMaster University located in Hamilton, Canada. The MNP platform technology originated from McMaster research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

20|20 OptimEyes Technologies

Ophthalmic Pharmaceuticals2020optimeyes.ca

20/20 OptimEyes Technologies is a pre-revenue McMaster University spin-out developing a patented mucoadhesive nanoparticle (MNP) drug delivery platform, with lead latanoprost glaucoma and cyclosporine dry eye product candidates targeting reduced dosing frequency and improved compliance.

What 20|20 OptimEyes Technologies does

20|20 OptimEyes Technologies is a Canadian biotechnology spin-out from McMaster University, founded in 2018 and headquartered in Hamilton, Ontario. The company has developed a proprietary MNP (Mucoadhesive Nanoparticles) drug delivery platform that encapsulates small-molecule active pharmaceutical ingredients in micelle structures with a mucoadhesive binding moiety, enabling sustained, localized release on mucosal surfaces. The core technology is protected by granted patents in the United States (Patent No. 10611908), Europe (EP3344232B1), Canada (CA2996910C), and Japan (JP2018529696A). In vivo data show OptimEyes MNPs achieve 6x greater drug concentration on the ocular surface at one week versus standard mucoadhesive nanoparticles, supporting a reduced dosing frequency advantage.

The company's lead product candidate is a latanoprost-based formulation for glaucoma designed for once-weekly dosing, targeting the up to 50% non-compliance rate observed with current daily topical regimens. A secondary candidate addresses dry eye disease with cyclosporine, demonstrated to achieve equivalent efficacy to Restasis in a rat model when dosed once every three days versus twice daily. The MNP platform is positioned as broadly applicable across ophthalmology, respiratory, urogenital, women's health, oncology, and CNS pathologies. The company pursues a dual go-to-market: internal product development for its own pipeline and external licensing collaborations with pharmaceutical partners for novel therapeutics applications.

20/20 OptimEyes operates as a pre-revenue, pre-commercial biotechnology company with a workforce of 1-10 employees. Revenue generation is anticipated through future product sales upon regulatory approval and through licensing fees, milestone payments, and royalty arrangements with strategic partners. The company has received institutional support from McMaster Seed Fund and Innovation Factory, and in September 2025 won the Blue Ticket Competition co-awarded by SpinUp at U of T Mississauga and Merck, providing wet-lab access, mentorship, and research network connectivity. CEO Frances Lasowski leads the organization. No commercial products, pricing, or revenue have been disclosed.

20|20 OptimEyes Technologies firmographics

Firmographics
Name
20|20 OptimEyes Technologies
Legal name
20|20 OptimEyes Technologies
Website
https://2020optimeyes.ca
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
20/20 OptimEyes Technologies is a pre-revenue McMaster University spin-out developing a patented mucoadhesive nanoparticle (MNP) drug delivery platform, with lead latanoprost glaucoma and cyclosporine dry eye product candidates targeting reduced dosing frequency and improved compliance.
Ownership category
akta.pro rank

20|20 OptimEyes Technologies industry classification

Industry
Product category
Ophthalmic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Nanotechnology (541713)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Mucosal drug delivery
  • Ophthalmic pharmaceuticals
  • Nanoparticle formulations
  • Drug delivery platform
  • Biotechnology research

Where 20|20 OptimEyes Technologies is headquartered

Location

Headquarters

HQ city
Hamilton
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

20|20 OptimEyes Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Internal Product Development: Developing proprietary drug formulations using existing generic therapeutics (e.g., latanoprost for glaucoma) through the MNP platform to create differentiated products with reduced dosing frequency. Revenue will be generated through product sales upon regulatory approval.
  2. Strategic Partnerships and Licensing: External collaborations with pharmaceutical partners to apply the MNP platform to novel therapeutics. The company offers in vitro and in vivo feasibility and optimization studies for partners. Revenue could come from licensing fees, milestone payments, and royalty arrangements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

20|20 OptimEyes Technologies product offering

Product offering

Core offering

20|20 OptimEyes Technologies develops and commercializes a proprietary Mucoadhesive Nanoparticles (MNP) drug delivery platform that encapsulates small-molecule drugs in mucoadhesive nanoparticles for sustained, localized release to mucosal surfaces. Its lead product candidate is a latanoprost-based once-weekly glaucoma formulation, and its secondary candidate is a cyclosporine-based dry eye disease formulation. The platform is licensed to pharmaceutical partners and applied across ophthalmology, respiratory, urogenital, women's health, oncology and CNS indications.

Product overview

20|20 OptimEyes Technologies offers the MNP (Mucoadhesive Nanoparticles) Platform as its core technology, a drug delivery system that encapsulates therapeutics in mucoadhesive nanoparticles for sustained, localized delivery to mucosal surfaces. The company's lead product is a latanoprost-based glaucoma treatment (currently in validation), and its secondary product addresses dry eye disease. Both products leverage the same MNP platform technology, which reduces dosing frequency (potentially to once-weekly) while improving bioavailability and patient compliance compared to conventional topical treatments.

Differentiator

Problem solved

Functional benefit

Products and services

  • MNP (Mucoadhesive Nanoparticles) Platform A next-generation mucoadhesive drug delivery platform that encapsulates small-molecule drugs in nanoparticles for sustained, localized release to mucosal surfaces, with improved bioavailability and reduced dosing frequency; licensed to pharmaceutical partners and applicable across ophthalmology, respiratory, urogenital, women's health, oncology and CNS indications.
  • Glaucoma Treatment (Latanoprost Formulation) Lead product candidate using the MNP platform with latanoprost as the active pharmaceutical ingredient for the treatment of glaucoma, designed for once-weekly dosing to address the up to 50% non-compliance rate with current daily topical eye drop regimens; targeted at chronic glaucoma patients and prescribing ophthalmologists.
  • Dry Eye Disease Treatment (Cyclosporine Formulation) Secondary product candidate using the MNP platform with cyclosporine for dry eye disease, offering improved tolerability and once-every-three-days dosing versus the twice-daily regimen of currently approved US treatments (Restasis, Cequa, Xiidra); targeted at patients suffering from dry eye disease with limited efficacy or tolerability issues on existing therapies.

Quantifiable outcome

  • 6x greater drug concentration on ocular surface at 1 week compared to standard MNP formulations
  • +4 more outcomes

Companies that use 20|20 OptimEyes Technologies

Customer profile

Segments3 records

Ideal customer profiles2 records

20|20 OptimEyes Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

20|20 OptimEyes Technologies partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • SpinUp at U of T MississaugacoreStrategic or Co-development Partner · 23 September 2025SpinUp is the first wet lab startup incubator at the University of Toronto Mississauga campus. 20/20 OptimEyes won the 2025 Blue Ticket Competition, receiving a free one-year membership providing access to subsidized wet lab space, equipment, entrepreneurship programming and resources in a state-of-the-art facility.
  • MerckcoreStrategic or Co-development Partner · 23 September 2025Merck (known as MSD outside US and Canada) is providing mentorship and guidance from seasoned Merck scientists and business leaders, along with access to U of T's research talent and network. The partnership supports breakthrough innovation in life sciences and aligns with Merck's commitment to groundbreaking health technologies.
  • McMaster UniversitycoreStrategic or Co-development Partner20/20 OptimEyes Technologies is a biotechnology spin-out company from McMaster University located in Hamilton, Canada. The MNP platform technology originated from McMaster research.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

20|20 OptimEyes Technologies competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

20|20 OptimEyes Technologies social profiles

Digital presence

20|20 OptimEyes Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

20|20 OptimEyes Technologies leadership team

Management profile

Number of profiles

Profiles1 record

20|20 OptimEyes Technologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

20|20 OptimEyes Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 20|20 OptimEyes Technologies

What does 20|20 OptimEyes Technologies do?

20|20 OptimEyes Technologies develops and commercializes a proprietary Mucoadhesive Nanoparticles (MNP) drug delivery platform that encapsulates small-molecule drugs in mucoadhesive nanoparticles for sustained, localized release to mucosal surfaces. Its lead product candidate is a latanoprost-based once-weekly glaucoma formulation, and its secondary candidate is a cyclosporine-based dry eye disease formulation. The platform is licensed to pharmaceutical partners and applied across ophthalmology, respiratory, urogenital, women's health, oncology and CNS indications.

Is 20|20 OptimEyes Technologies a public or private company?

20|20 OptimEyes Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was 20|20 OptimEyes Technologies founded?

20|20 OptimEyes Technologies was founded in 2018. It employs 1 to 10 people.

Where is 20|20 OptimEyes Technologies based?

20|20 OptimEyes Technologies is headquartered in Hamilton, Canada, in the North America region.

How does 20|20 OptimEyes Technologies make money?

Two revenue lines are on record. Internal Product Development is the primary driver. The others are strategic Partnerships and Licensing.

Does 20|20 OptimEyes Technologies have an API?

No public API is recorded for 20|20 OptimEyes Technologies.

What industry is 20|20 OptimEyes Technologies in?

20|20 OptimEyes Technologies's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts), with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales